Principal Investigator
Byron Lam
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20221027
Clinical Trial Summary
A Phase 2/3, Randomized, Controlled, Masked, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Two Doses of AGTC-501, a Recombinant Adeno-associated Virus Vector Expressing RPGR (rAAV2tYF-GRK1-RPGR), Compared to an Untreated Control Group in Male Subjects with X-linked Retinitis Pigmentosa Confirmed by a Pathogenic Variant in the RPGR Gene
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other